JP2022545005A5 - - Google Patents
Info
- Publication number
- JP2022545005A5 JP2022545005A5 JP2022511096A JP2022511096A JP2022545005A5 JP 2022545005 A5 JP2022545005 A5 JP 2022545005A5 JP 2022511096 A JP2022511096 A JP 2022511096A JP 2022511096 A JP2022511096 A JP 2022511096A JP 2022545005 A5 JP2022545005 A5 JP 2022545005A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- egfr
- kras
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962890119P | 2019-08-22 | 2019-08-22 | |
| US62/890,119 | 2019-08-22 | ||
| PCT/US2020/047090 WO2021034992A1 (en) | 2019-08-22 | 2020-08-20 | Method of treating kras-associated cancers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545005A JP2022545005A (ja) | 2022-10-24 |
| JP2022545005A5 true JP2022545005A5 (cg-RX-API-DMAC7.html) | 2023-08-28 |
| JP7602272B2 JP7602272B2 (ja) | 2024-12-18 |
Family
ID=74660044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022511096A Active JP7602272B2 (ja) | 2019-08-22 | 2020-08-20 | Ｋｒａｓ関連がんを治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220273643A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017489B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7602272B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220050143A (cg-RX-API-DMAC7.html) |
| CN (2) | CN119454706A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020334069B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022003165A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150759A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL290454B2 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022002108A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034992A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| EP3849537B1 (en) | 2018-09-10 | 2024-10-23 | Mirati Therapeutics, Inc. | Combination therapies |
| EA202190749A1 (ru) | 2018-09-10 | 2021-07-09 | Мирати Терапьютикс, Инк. | Способы комбинированной терапии |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| JP2022500385A (ja) | 2018-09-10 | 2022-01-04 | ミラティ セラピューティクス， インコーポレイテッド | 組み合わせ療法 |
| MX2021002804A (es) | 2018-12-05 | 2021-07-15 | Mirati Therapeutics Inc | Terapias de combinacion. |
| EP3908283A4 (en) | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
| MX2022002465A (es) | 2019-08-29 | 2022-05-19 | Mirati Therapeutics Inc | Inhibidores de kras g12d. |
| WO2021061749A1 (en) | 2019-09-24 | 2021-04-01 | Mirati Therapeutics, Inc. | Combination therapies |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| JP2023553492A (ja) | 2020-12-15 | 2023-12-21 | ミラティ セラピューティクス， インコーポレイテッド | アザキナゾリン汎ＫＲａｓ阻害剤 |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CA3214172A1 (en) * | 2021-04-02 | 2022-10-06 | Mukesh K. Nyati | Combination therapy for cancer treatment |
| WO2023003417A1 (ko) * | 2021-07-22 | 2023-01-26 | 국립암센터 | Kras 돌연변이 특이적 저해제 및 이를 포함하는 암 예방 또는 치료용 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| CA2612183C (en) * | 2005-06-28 | 2015-08-11 | Genentech, Inc. | Egfr and kras mutations |
| WO2010114922A1 (en) * | 2009-03-31 | 2010-10-07 | Agios Pharmaceuticals, Inc. | Methods of treating cancer having an aberrant egfr or kras genotype |
| WO2012064642A1 (en) * | 2010-11-08 | 2012-05-18 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| US20140256767A1 (en) | 2011-10-31 | 2014-09-11 | The Broad Institute, Inc. | Direct inhibitors of keap1-nrf2 interaction as antioxidant inflammation modulators |
| WO2014176475A2 (en) | 2013-04-26 | 2014-10-30 | The Regents Of The University Of Michigan | Egfr inhibitors and uses thereof |
| EP3755323A4 (en) * | 2018-02-23 | 2021-11-24 | The Regents Of The University Of Michigan | EGFR DIMER DISRUPTORS AND THEIR USES |
-
2020
- 2020-08-20 MX MX2022002108A patent/MX2022002108A/es unknown
- 2020-08-20 CA CA3150759A patent/CA3150759A1/en active Pending
- 2020-08-20 JP JP2022511096A patent/JP7602272B2/ja active Active
- 2020-08-20 AU AU2020334069A patent/AU2020334069B2/en active Active
- 2020-08-20 EP EP20854314.0A patent/EP4017489B1/en active Active
- 2020-08-20 IL IL290454A patent/IL290454B2/en unknown
- 2020-08-20 WO PCT/US2020/047090 patent/WO2021034992A1/en not_active Ceased
- 2020-08-20 BR BR112022003165A patent/BR112022003165A2/pt unknown
- 2020-08-20 US US17/634,265 patent/US20220273643A1/en not_active Abandoned
- 2020-08-20 CN CN202411400491.9A patent/CN119454706A/zh active Pending
- 2020-08-20 CN CN202080059528.XA patent/CN114286676A/zh active Pending
- 2020-08-20 KR KR1020227007201A patent/KR20220050143A/ko active Pending